A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nabpaclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer

被引：0
|
作者：
Vincent, Picozzi [1 ]
Vaibhav, Sahai [2 ]
Diane, Simeone [2 ]
Caio, Rocha Lima [3 ]
Allyson, Ocean [4 ]
Philip, Philip [5 ]
Wasif, Saif [6 ]
Aparna, Kalyan [7 ]
Michael, Ondovik [8 ]
Jack, Shiansong Li [8 ]
Chrystal, Louis [8 ]
机构：
[1] Virginia Mason, Seattle, WA USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Gibbs Canc Ctr, Res Inst, Spartanburg, SC USA
[4] Weill Cornell Med Coll, New York, NY USA
[5] Karmanos Canc Ctr, Detroit, MI USA
[6] Tufts Med Ctr, Boston, MA USA
[7] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[8] Celgene Corp, Summit, NJ USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-231
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase II study of oxaliplatin, 5-FU and leucovorin in patients with relapsed ovarian cancer
    Thomas, AL
    Osman, A
    Morgan, B
    Khanna, S
    Symonds, RP
    O'Byrne, K
    BRITISH JOURNAL OF CANCER, 2001, 85 : 57 - 57
  • [22] Bevacizumab plus oxaliplatin (LOHP), leukovorin (LV)/5-fluorouracil (5-FU) (FOLFOX4) as first line treatment of patients with metastatic colorectal cancer(MCC)
    Emmanouilides, C.
    Sfakiotaki, G.
    Souglakos, J.
    Mavroudis, D.
    Androulakis, N.
    Kavlaki, A.
    Kotsakis, A.
    Diamandidou, E.
    Touroutoglou, N.
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2006, 17 : 70 - 71
  • [23] Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan
    Tai, CJ
    Liu, JH
    Chen, WS
    Lin, JK
    Wang, WS
    Yen, CC
    Chiou, TJ
    Chen, PM
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (03) : 136 - 140
  • [24] Phase II trial of oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for advanced biliary tract adenocarcinoma.
    Porschen, R
    Nehls, O
    Bermann, A
    Burkart, C
    Gregor, M
    GASTROENTEROLOGY, 1999, 116 (04) : A487 - A487
  • [25] GEMCITABINE (GEM) PLUS OXALIPLATIN, FOLINIC ACID (FA) AND 5-FLUOROURACIL (5-FU) IN PATIENTS WITH ADVANCED GASTRIC CANCER
    Correale, Pierpaolo
    Fulfaro, Fabio
    Cicero, Giuseppe
    Bajardi, Emilio
    Marsili, Stefania
    Petrioli, Roberto
    Vuolo, Giuseppe
    Guarnieri, Alfredo
    Gebbia, Nicola
    Francini, Guido
    ANNALS OF ONCOLOGY, 2004, 15 : 70 - 71
  • [26] Phase III trial of capecitabine plus oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC)
    Rothenberg, M. L.
    Navarro, M.
    Butts, C.
    Bang, Y.
    Cox, J. V.
    Goel, R.
    Gollins, S.
    Siu, L. L.
    Cunningham, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer
    Fischer, GeorgeA.
    Kuo, Timothy
    Ramsey, Meghan
    Schwartz, Erich
    Rouse, RobertV.
    Cho, Cheryl D.
    Halsey, Joanne
    Sikic, Branimir I.
    CLINICAL CANCER RESEARCH, 2008, 14 (21) : 7074 - 7079
  • [28] Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy
    Falcone, A
    Pfanner, E
    Brunetti, I
    Allegrini, G
    Lencioni, M
    Galli, C
    Masi, G
    Danesi, D
    Antonuzzo, A
    Del Tacca, M
    Conte, PF
    TUMORI, 1998, 84 (06) : 666 - 668
  • [29] Palliative therapy for advanced biliary tract carcinoma with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV).
    Nehis, O
    Klump, B
    Gregor, M
    Porschen, R
    GASTROENTEROLOGY, 2000, 118 (04) : A523 - A523
  • [30] 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: A single-institute study
    Bir, Arvinder
    Tan, Wei
    Wilding, Gregory E.
    Lombardo, Jeffery
    Fakih, Marwan G.
    ONCOLOGY, 2007, 72 (1-2) : 4 - 9
12345